About the Company
chinook therapeutics (nasdaq: kdny) is a clinical-stage biotechnology company developing precision medicines for kidney diseases. kidney diseases are a severe and growing problem worldwide, with a lack of effective treatments often leading to dialysis, transplantation and high costs to health care systems. drug development in kidney diseases is experiencing a resurgence due to greater understanding of disease biology, utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $KDNY News
Vertex to Pay $4.9 Billion for Kidney Disease Drug Developer
Vertex Pharmaceuticals Inc. agreed to buy Alpine Immune Sciences Inc. for a total equity value of about $4.9 billion, adding ...
New report shows sustained growth for Washington's life science industry
The life science industry had a statewide economic impact of $38.8 billion in 2022, up from $35.3 billion in 2021, according ...
Eliem pursues acquisition of New Jersey biotech after halting programs
With the Tenet deal, announced Thursday, Eliem said it is now focusing on Tenet's candidate TNT119, which is aimed at a ...
Report: Life Sciences Industry Economic Impact Approaches $40B in Washington
The life sciences industry in Washington state produced a total economic impact of $38.8 billion in 2022, directly employed ...
Three Finalists Announced for the 2024 Bloom Burton Award
Recognizing the Year's Most Significant Contributions to Canada's Innovative Healthcare Industry Toronto, Ontario--( - April ...
Top Analyst Reports for Novartis, American Express & ConocoPhillips
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novartis AG (NVS), American Express ...
The Zacks Analyst Blog Highlights Novartis, American Express, ConocoPhillips, Netflix and Schlumberger
The Zacks Daily presents the best research output of our analyst team. Today's Daily features new research reports on 16 ...
Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'
Vertex Pharmaceuticals (VRTX) to acquire Alpine Immune Sciences (ALPN) for $4.9b in cash. Check out why I think this deal may ...
Kohr Explores: 82nd Avenue of Roses Parade takes to the streets Saturday
PORTLAND, Ore. ( KOIN) — This weekend, the 82nd Avenue of Roses Parade returns to the Rose City. The 18th annual parade kicks ...
2 shot in Chester on Avenue of the States
Chester police confirm two people were shot in the area of the1000 block of the Avenue of the States about 5:30 Sunday ...
DelveInsight Business Research, LLP: Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsight
The dynamics of the Alport syndrome market are anticipated to change in the coming years owing to the improvement in the rise in healthcare spending across the world. LAS VEGAS, April ...
Bloom Burton & Co. Inc.: Three Finalists Announced for the 2024 Bloom Burton Award
Bloom Burton & Co. is pleased to announce the finalists for the 2024 Bloom Burton Award. Bestowed annually and nominated by the public at large, the ...
Loading the latest forecasts...